Redefining the p53 response element (Proceedings of the National Academy of Sciences of the United States of America (2009) 106, 34, (14373-14378) DOI:10.1073/pnas.0903284106));Redefining the p53 response element

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 34, 2009, Pages 14373-14378

  Wang, Bei ^a   Xiao, Ziwei ^b   Ren, Ee Chee ^a,b  

^a AGENCY FOR SCIENCE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Activation; Cancer; Gene regulation; Repression; Transcription

Indexed keywords

NUCLEOTIDE; PROTEIN P21; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; DNA RESPONSIVE ELEMENT; GENE SEQUENCE; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LASP1 GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING;

EID: 70149101589     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0909457106     Document Type: Erratum

References (39)

1. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310.
2. Vousden KH, Lu X (2002) Live or let die: The cell's response to p53. Nat Rev Cancer 2:594-604. (Pubitemid 37328926)
3. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nat Genet 1:45-49.
4. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW (1992) A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12:2866-2871.
5. Inga A, Storici F, Darden TA, Resnick MA (2002) Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 22:8612-8625. (Pubitemid 35397176)
6. Jordan JJ, et al. (2008) Noncanonical DNA motifs as transactivation targets by wild-type and mutant p53. PLoS Genet 4:e1000104.
7. Osada M, et al. (2005) Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol 25:6077-6089. (Pubitemid 40946559)
8. Ginsberg D, Mechta F, Yaniv M, Oren M(1991) Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 88:9979-9983. (Pubitemid 21915758)
9. Ho J, Benchimol S (2003) Transcriptional repression mediated by the p53 tumor suppressor. Cell Death Differ 10:404-408. (Pubitemid 36636906)
10. Muller M, et al. (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188:2033-2045. (Pubitemid 28562520)
11. Sax JK, et al. (2002) BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 4:842-849.
12. Gopalkrishnan RV, Lam EW, Kedinger C (1998) The p53 tumor suppressor inhibits transcription of the TATA-less mouse DP1 promoter. J Biol Chem 273:10972-10978. (Pubitemid 28204937)
13. Krause K, et al. (2000) The tumor suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res 28:4410-4418. (Pubitemid 30838236)
14. Li C, Lin M, Liu J (2004) Identification of PRC1 as the p53 target gene uncovers a novel function of p53 in the regulation of cytokinesis. Oncogene 23:9336-9347. (Pubitemid 40069666)
15. May P, May E (1999) Twenty years of p53 research: Structural and functional aspects of the p53 protein. Oncogene 18:7621-7636. (Pubitemid 30052689)
16. Mirza A, et al. (2003) Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22:3645-3654. (Pubitemid 36765324)
17. Spurgers KB, et al. (2006) Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem 281:25134-25142.
18. Wang L, et al. (2001) Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J Biol Chem 276:43604-43610. (Pubitemid 37383920)
19. Zhao R, et al. (2000) Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 14:981-993. (Pubitemid 30253006)
20. Menendez D, et al. (2006) A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci USA 103:1406-1411. (Pubitemid 43191178)
21. Tomso DJ, et al. (2005) Functionally distinct polymorphic sequences in thehumangenome that are targets for p53 transactivation. Proc Natl Acad Sci USA 102:6431-6436.
22. Veprintsev DB, Fersht AR (2008) Algorithm for prediction of tumor suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res 36:1589-1598.
23. Wei CL, et al. (2006)Aglobalmapof p53 transcription-factor binding sites in thehuman genome. Cell 124:207-219.
24. Wang B, Feng P, Xiao Z, Ren EC (2009) LIM and SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. J Hepatol 50:528-537.
25. Jagelska E, Brazda V, Pospisilova S, Vojtesek B, Palecek E (2002) New ELISA technique for analysis of p53 protein/DNA binding properties. J Immunol Methods 267:227-235. (Pubitemid 34880036)
26. Horvath MM, Wang X, Resnick MA, Bell DA (2007) Divergent evolution of human p53 binding sites: Cell cycle versus apoptosis. PLoS Genet 3:e127. (Pubitemid 47203978)
27. Lefort K, et al. (2007) Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKα kinases. Genes Dev 21:562-577. (Pubitemid 46409471)
28. Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402-412. (Pubitemid 351574202)
29. Im HJ, Pittelkow MR, Kumar R (2002) Divergent regulation of the growth-promoting gene IEX-1 by the p53 tumor suppressor and Sp1. J Biol Chem 277:14612-14621. (Pubitemid 34952528)
30. Wu GS, Saftig P, Peters C, el-Deiry WS (1998) Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 16:2177-2183.
31. Miled C, Pontoglio M, Garbay S, Yaniv M, Weitzman JB (2005) A genomic map of p53 binding sites identifies novel p53 targets involved in an apoptotic network. Cancer Res 65:5096-5104. (Pubitemid 40827318)
32. Burns TF, Fei P, Scata KA, Dicker DT, el-Deiry WS(2003) Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23:5556-5571.
33. Weinberg RL, Veprintsev DB, Bycroft M, Fersht AR (2005) Comparative binding of p53 to its promoter and DNA recognition elements. J Mol Biol 348:589-596. (Pubitemid 40515671)
34. Balagurumoorthy P, Lindsay SM, Harrington RE (2002) Atomic force microscopy reveals kinks in the p53 response element DNA. Biophys Chem 101-102:611-623. (Pubitemid 35462075)
35. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: Cancer implications. Nat Rev Cancer 9:95-107.
36. Latchman DS (2001) Transcription factors: Bound to activate or repress. Trends Biochem Sci 26:211-213.
37. Tokino T, et al. (1994) p53 tagged sites from human genomic DNA. Hum Mol Genet 3:1537-1542. (Pubitemid 24295446)
38. Crooks GE, Hon G, Chandonia JM, Brenner SE (2004) WebLogo: A sequence logo generator. Genome Res 14:1188-1190.
39. Schneider TD, Stephens RM (1990) Sequence logos: A new way to display consensus sequences. Nucleic Acids Res 18:6097-6100. (Pubitemid 20364672)